Bruno Morgan Selected Research

vatalanib (PTK787)

4/2014	Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
10/2010	A phase 2 study of vatalanib in metastatic melanoma patients.
6/2006	Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
6/2005	Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
11/2003	Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruno Morgan Research Topics

Disease

9	Neoplasms (Cancer) 01/2017 - 06/2003
9	Neoplasm Metastasis (Metastasis) 08/2015 - 06/2003
8	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 06/2003
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2014 - 06/2010
2	Mesothelioma 01/2022 - 01/2021
2	Disease Progression 01/2021 - 10/2010
2	Adenocarcinoma 02/2019 - 06/2013
2	Melanoma (Melanoma, Malignant) 10/2010 - 06/2006
1	Pulmonary Embolism 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Malignant Mesothelioma 01/2022
1	Alopecia (Baldness) 01/2022
1	Ascites 01/2022
1	Sepsis (Septicemia) 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022
1	Infections 01/2022
1	Vomiting 01/2022
1	Urinary Tract Infections (Urinary Tract Infection) 01/2022
1	Thrombosis (Thrombus) 01/2022
1	Penile Neoplasms (Penile Cancer) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017
1	Drowning 01/2017
1	Lung Neoplasms (Lung Cancer) 07/2014
1	Necrosis 02/2011
1	Liver Neoplasms (Liver Cancer) 02/2011
1	Renal Cell Carcinoma (Grawitz Tumor) 09/2007
1	Spontaneous Remission 09/2007
1	Abdominal Pain (Pain, Abdominal) 03/2007
1	Stomach Ulcer (Gastric Ulcer) 03/2007

Drug/Important Bio-Agent (IBA)

7	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2003
5	vatalanib (PTK787)IBA 04/2014 - 11/2003
4	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2019 - 03/2007
4	CurcuminIBA 01/2019 - 10/2004
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2006 - 06/2003
3	Fluorouracil (Carac)FDA LinkGeneric 08/2015 - 03/2007
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2017 - 06/2013
2	Leucovorin (Folinic Acid)FDA Link 03/2015 - 03/2007
2	Tyrosine Kinase InhibitorsIBA 10/2010 - 06/2006
2	Biological ProductsIBA 06/2006 - 06/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2006 - 06/2003
1	vinflunineIBA 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022
1	abemaciclibIBA 01/2022
1	PlatinumIBA 01/2022
1	rucaparibIBA 01/2021
1	HydrolasesIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Capecitabine (Xeloda)FDA Link 02/2019
1	Epirubicin (Ellence)FDA LinkGeneric 02/2019
1	Indicators and Reagents (Reagents)IBA 01/2017
1	Gemcitabine FDA Link 01/2017
1	Pharmaceutical PreparationsIBA 01/2017
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 06/2013
1	Docosahexaenoic AcidsIBA 06/2013
1	Bortezomib (Velcade)FDA Link 06/2010
1	Pemetrexed (MTA)FDA Link 06/2010
1	Yttrium-90IBA 03/2007
1	Phosphotransferases (Kinase)IBA 11/2003
1	Tyrosine (L-Tyrosine)FDA Link 11/2003

Therapy/Procedure

7	Drug Therapy (Chemotherapy) 01/2022 - 10/2004
5	Therapeutics 01/2022 - 03/2007
2	Microspheres (Microsphere) 02/2011 - 03/2007
1	Precision Medicine 07/2014
1	Parenteral Nutrition 06/2013
1	Biological Therapy 04/2011
1	Brachytherapy 02/2011
1	Nephrectomy 09/2007